West Pharmaceutical Services (WST) 8-K Regulation FD Disclosure

1

Donald E. Morel

Chairman and Chief Executive Officer

William J. Federici

Vice President and Chief Financial Officer

Investor Relations Contact:

Michael A. Anderson

Vice President and Treasurer

mike.anderson@westpharma.com

Jefferies 2010 Global Life Sciences Conference

June 9, 2010

NYSE: WST

westpharma.com

All trademarks and registered trademarks are the property of West Pharmaceutical Services, Inc., unless noted otherwise.

2

This presentation contains forward-looking statements, within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, that are based on management’s beliefs and assumptions, current
expectations, estimates and forecasts.Statements that are not historical facts, including
statements that are preceded by, followed by, or that include, words such as “estimate,”
“expect,” “intend,” “believe,” “plan,” “anticipate” and other words and terms of similar meaning
are forward-looking statements.West’s estimated or anticipated future results, product
performance or other non-historical facts are forward-looking and reflect our current
perspective on existing trends and information.

Many of the factors that will determine the Company’s future results are beyond the ability of
the Company to control or predict.These statements are subject to known or unknown risks
or uncertainties, and therefore, actual results could differ materially from past results and
those expressed or implied in any forward-looking statement.You should bear this in mind as
you consider forward-looking statements. A non-exclusive list of important factors that may
affect future results may be found in West’s filings with the Securities and Exchange
Commission, including our annual report on Form 10-K and our periodic reports on Form 10-
Q and Form 8-K.

You should evaluate any statement in light of these important factors.

Safe Harbor Statement

3

Corporate Profile

•For more than eighty years, a
global leader in the
development and manufacture
of components and systems for
injectable drug delivery

–Vial closure systems

–Prefillable syringe components

–Components for diagnostics

–Devices and device sub-
assemblies

–Safety and administration
systems

•Market capitalization $1.4 billion

•Diverse, stable customer base

•Global footprint

Devices

Proprietary

Products

4

West Pharmaceutical Services Today

●32 plants in 10 countries

●34 sales offices

●7 technical centers

6,000 employees worldwide

5

Sales and Income from Continuing Operations
($ in millions)

6

First Quarter 2010 Results

$ millions, except per share data	2010	2009
Net Sales	$274.7	$242.4
Gross Margin	30%	29%
Research & Development	$5.4	$4.3
Selling, General & Administrative Exp.	$46.6	$42.9
Net Income	$19.8	$15.4
Diluted EPS - GAAP	$0.57	$0.46
Diluted EPS - Non-GAAP	$0.58	$0.42

First quarter 2010 diluted EPS - Non-GAAP excludes a net ($0.01) per share forrestructuring charges.

First quarter 2009 diluted EPS - Non-GAAP excludes a net $0.04 per share for discrete tax benefits and Tech
restructuring charges.

7

Consolidated First Quarter 2010 Operating Results
($ millions)

•Ex-Currency, Growth was:

$ 10.0Gross Profit (14.4%)

$ 6.0Adjusted Operating Profit (27.4%)

•Currency translation added:

$ 9.8 Revenue

$ 2.9 Gross Profit

$ 1.6 OperatingProfit

•Comparative result drivers:

–Favorable volume and mix,
increased pricing and increased
efficiencies

–Increasing labor, overhead and
depreciation costs

–SG&A cost containment

8

•Global economic conditions unsettled, however

•Global pharmaceutical revenue growth projected to
be 4-6% (per IMS) on modest unit growth

•North America growth projected at 4.5 - 5.5%

•Europe growth moderate 2-4%

•Emerging economies should grow > 10% (India, China, Brazil)

•Managing through:

–Impact of US healthcare legislation

–Industry mergers and consolidation

–Changing customer order/inventory patterns

Challenging Business Environment

9

2010 Priorities

•Establishing the new organization

•Evolution of a global, cross-business
unit selling model

•Crystal Zenith® syringe system

•The Global Quality Initiative

10

Pharmaceutical Packaging
Systems

(How drugs are contained)

Primary Container Solutions

Pharmaceutical Delivery
Systems

(How drugs are administered)

Administration Systems

Business Unit Re-alignment

•Safety systems (NovaGuard, éris)

•Reconstitution systems -
Medimop

•CZ prefillable syringe systems

•Advanced Injection Systems
(Confidose)

•Tech Group Contract
Manufacturing

•Small volume parenteral
packaging

•Large volume parenteral
packaging

•Prefillable syringe components

•Disposable medical device
components

•Diagnostic, dental, veterinary
packaging

11

Five-Year Growth Opportunity

$2 billion combined markets for safety,
prefilled and auto-injectors, with unit
growth 6-12%, depending on product and
therapeutic segment

Strategic Planning Goals:

•Projected 2014 sales of $0.6 billion

•Projected 2014 Operating margin: 20%

$1.5 billion market for components with unit
growth 0% to 8% per year, depending on
product and therapeutic segment

Strategic Planning Goals:

•Projected 2014 sales of $1.0 billion

•Projected 2014 Operating margin: 20%

Pharmaceutical

Packaging Systems

Primary Container Solutions

Pharmaceutical Delivery
Systems

Administration Systems

Consolidated 2014 Planning Objectives

•2014 Sales: $1.6 billion

•2014 Operating Margin: 19%

•2014 Consolidated ROIC: 17%

12

Long Term Business Drivers

•Demographics

•Growth in Biologics & Vaccines

•Requirement for easy, safe,
accurate dosing

•Combination product growth

•Generic growth

•Increasing global access to
advanced healthcare

West supplies sophisticated
packaging systems for the top 20
biologic drugs (by sales) currently
on the market.

13

Category	Key Customers	Projected Growth
Diabetes		> 10 %
Oncology		> 10 %
Vaccines		> 10 %
Autoimmune		>8%

IMS April 2010 Report; Business Insights 2009; GBI Research 2009

Therapeutic Category Growth Expectations

14

Packaging Systems Growth Strategy

West’s Competitive Advantages:

•Unmatched expertise in drug -
material interactions

•Market leader in packaging for
biologics

•Protected IP: Proprietary materials
and processing technology - Drug
Master File (DMF) 1546

•Regulatory barriers to entry:

US NDAs and ANDAs
require proof of stability

•Global manufacturing footprint

•Global technical support

Pharmaceutical Packaging
Systems

(How drugs are contained)

Primary Container Solutions

•Therapeutic segment focus

•Generate incremental value per
unit

•Leverage changing regulatory
environment

•Optimize manufacturing
productivity

•Strategic acquisitions

•Geographic expansion

•China

•India

15

Value Proposition

PROPRIETARY

PRODUCTS

Revenue and

Margin
Opportunity

Disposable Device

Disposable Device

Components

Components

Westar® RS

Mix2Vial®

NovaGuard™

éris™

Westar® RU

Standard
Components

Standard
Components

Consumer

Consumer

Products

Products

Packaging

Delivery

16

High-Value Products Drive Growth

Westar® RS

State of the art

ready-to-sterilize

elastomer closures

Westar® RU

State of the art

ready-to-use

syringe plungers

and closures

Envision™

Technically advanced,

automated vision

inspection system

NovaPure™

Unrivaled

quality….by

design

17

Faster Growth of High-Value Products
Pharmaceutical Packaging Systems

18

Delivery Systems Growth Strategy

•Concentrate on systems for unmet
market needs

•Build market share in multi-
component systems for drug
administration utilizing Daikyo CZ as
a platform technology

•Production supported by existing
design, multi-material molding, and
assembly capabilities

•Expand through innovation and
strategic technology acquisitions

Pharmaceutical Packaging
Systems

Primary Container Solutions

Pharmaceutical Delivery
Systems

Administration Systems

•Therapeutic segment focus

•Generate incremental value per
unit

•Leverage changing regulatory
environment

•Optimize manufacturing
productivity

•Strategic acquisitions

•Geographic expansion

•China

•India

19

CZ Syringe +
ConfiDose®

West Solutions to Biopharma
Lifecycle Management

$1,000,000
Components

$55,000,000

20

Pharmaceutical Delivery Systems
Key Programs

Vial2Bag™

Mix2Vial®

MixJect®

NovaGuard™ Safety
Needle Device

(luer-lock syringe)

ConfiDose®
Auto-injector

Daikyo Crystal Zenith®

éris™

Safety Needle Device

(fixed-needle syringe)

21

Daikyo Crystal Zenith®Insert Needle Syringe

Drug and Pharma Company Benefits

•Silicone oil free

•Tungsten free

•Glue free

•Lower dead space

•Reduced risk: breakage, waste, recall

Auto-Injector Benefits

•Consistent break loose and glide forces

•Break resistant

•Tight dimensional tolerances

•Design flexibility of plastics

Highest Quality

•100% vision inspection

•X-ray inspection of needle

•Automated, clean production process

Daikyo Crystal Zenith, Crystal Zenith and CZ are trademarks and registered trademarks of Daikyo Seiko Ltd.

22

Our Long Term Focus

•Pharmaceutical Packaging Systems

–Organic growth (on average) of 3-5% per year

–Margin expansion through improved operating efficiency, product mix

–Capital investments targeted at enhanced quality and value

•Pharmaceutical Delivery Systems

–Deliver the potential of Daikyo CZ products

–Increase healthcare-consumable contract manufacturing revenue

–Grow proprietary safety and delivery system businesses

•Financial discipline

–Operating cash flow: Discretionary SG&A, R&D and capital spending
that are supported by revenue growth.

–Deliver returns on invested capital that regularly exceed weighted
average cost of capital.

–Align incentives with financial performance and value creation

23

Summary

•Well positioned

–Substantial market share

–Proprietary technology

–Diversified customer base

–Global footprint

•Significant Growth Potential

–Strength in new product pipeline

–Preferred products for biologics

•The financial strength to invest

–Reliable operating cash flow

–Balance sheet strength

•An experienced team

Injectable Container Solutions

Advanced
Injection
Systems

Prefillable Syringe Systems

Safety and Administration
Systems

24

Donald E. Morel

Chairman and Chief Executive Officer

William J. Federici

Vice President and Chief Financial Officer

Investor Relations Contact:

Michael A. Anderson

Vice President and Treasurer

mike.anderson@westpharma.com

Jefferies 2010 Global Life Sciences Conference

June 9, 2010

NYSE: WST

westpharma.com